Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 68Recurrence 10Lymphoma 7Neoplasms, Plasma Cell 5Waldenstrom Macroglobulinemia 4Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Hematologic Neoplasms 3Ovarian Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Kidney Neoplasms 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Adenoma, Pleomorphic 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1

Interventions

Dexamethasone 7Bortezomib 4Lenalidomide 3pomalidomide 2glucarpidase 2Kidney Transplantation 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1osimertinib 1mirabegron 1gamma-Glutamyl Hydrolase 1copanlisib 1carfilzomib 1Zoledronic Acid 1Urinalysis 1Topotecan 1Thalidomide 1Tablets 1Stents 1Sitagliptin Phosphate 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Renal Insufficiency × carfilzomib × Clear all
NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Amgen

Phase 2 Completed
50 enrolled 33 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡